Clinical Trials for Atopic Dermatitis (Eczema)

Do you have poorly controlled Atopic Dermatitis (eczema)?

If so, you may be eligible to take part in a National Institutes of Health-sponsored research study to examine the effect of a new treatment called dupilumab on your skin disease.

You may be eligible if:

  • You are a male or female between the ages of 18 and 65 years old
  • You have moderate to severe atopic dermatitis and have at least three active areas of disease on your arms or legs
  • You have not previously received the FDA-approved drug, dupilumab, (also called Dupixent) for the treatment of your atopic dermatitis or any other allergic disease

What’s involved?

  • About 10 visits to the clinic over a 6 month time period, plus phone calls
  • Blood and skin sample collection, including skin biopsy
  • Subcutaneous (just under the skin) injections of dupilumab or placebo

If you decide to participate you will receive:

  • Ten or 16 weeks of treatment with dupilumab (Dupixent) at no cost to you or your insurance provider
  • Study related medical exams
  • Blood test results
  • Financial compensation

For more information, please contact:

Study Investigator: Dr. Anna De Benedetto
UF Health Department of Dermatology

(352) 594-1547 Study Coordinator
4037 NW 86th Terrace- 4th Floor,
Gainesville, FL 32606